ABERA BIOSCIENCE AB
Research ABERA BIOSCIENCE AB (8WK) on Bullrun: market cap EUR 15.83M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker8WK
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 15.83M
- Financial periodQ4 2025
- Net income-EUR 8.80M
- Free cash flow-EUR 887.00K
Valuation Snapshot
latest market cap is EUR 15.83M.
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA.
Frequently asked questions
What is ABERA BIOSCIENCE AB's market cap?
ABERA BIOSCIENCE AB's market capitalization is EUR 15.83M.
What does ABERA BIOSCIENCE AB do?
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally.